Tuberculosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
1) How can we shorten chemotherapy? | 1) How can we shorten chemotherapy? | ||
2)How can the interval between the therapy reduced ? | 2) How can the interval between the therapy reduced ? | ||
3) How can new drugs be developed ? | 3) How can new drugs be developed ? | ||
| Line 15: | Line 15: | ||
5) Role of immunomodulation | 5) Role of immunomodulation | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 500px;" align=center | |||
|valign=top| | |||
|+ | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Drug}} | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Phase}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Delamanid | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase III | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Bedaquiline | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase III | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |PA-824 | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase IIB | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Sutezolid | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |AZD-5847 | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |SQ-109 | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Linezolid | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Clofazimine | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Moxifloxacin | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase III | |||
|} | |||
==References== | ==References== | ||
Revision as of 14:24, 25 September 2014
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberculosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Tuberculosis future or investigational therapies |
|
Tuberculosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Tuberculosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Future investigations
In future therapies the following questions must be pondered on.
1) How can we shorten chemotherapy?
2) How can the interval between the therapy reduced ?
3) How can new drugs be developed ?
4) What is the best therapy for tuberculosis with HIV ?
5) Role of immunomodulation
| Drug | Phase |
|---|---|
| Delamanid | Phase III |
| Bedaquiline | Phase III |
| PA-824 | Phase IIB |
| Sutezolid | Phase II |
| AZD-5847 | Phase II |
| SQ-109 | Phase II |
| Linezolid | Phase II |
| Clofazimine | Phase II |
| Moxifloxacin | Phase III |